CompletedNot Applicable

Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin

United States301 participantsStarted 2007-05

Plain-language summary

RATIONALE: New ways to find out about hearing loss after treatment with chemotherapy may improve the ability to plan cancer treatment and may help patients live more comfortably. PURPOSE: This clinical trial is assessing ear damage in young cancer patients treated with cisplatin.

Who can participate

Age range1 Year – 18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

DISEASE CHARACTERISTICS: * Planning to undergo treatment with any cisplatin-containing therapeutic regimen for cancer * Treatment does not need to be on a COG therapeutic study * Planning to enroll on clinical trial ACCL0431 PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * See Disease Characteristics * No prior cisplatin

What they're measuring

Incidence of patients with ototoxicity according to Common Toxicity Criteria, American-Speech-Language-Hearing Association, and Brock's criteria

Timeframe: Length of study

Proportion of patients who undergo assessments using ultrahigh frequency (UHF) and evoked otoacoustic emission (OAE) testing

Timeframe: Length of study

Proportion of patients with complete standard audiometry data (excluding UHF and OAE evaluations)

Timeframe: Length of Study

Trial details

NCT IDNCT00458887

SponsorChildren's Oncology Group

Sponsor typeNETWORK

Study typeOBSERVATIONAL

Primary completion2015-01

View on ClinicalTrials.gov More Ototoxicity trials